Margaret von Mehren, MD, discusses the rationale for evaluating ripretinib in patients with heavily pretreated advanced GIST in the phase III INVICTUS trial, which was presented at the ESMO Congress 2019.
Videos
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
EHA 2026 Multiple Myeloma Highlights Have Worldwide Impact
2
Oncologists Perceive Shift Away from Surgery in Progressive Desmoid Tumors
3
The Gap Between What Oncologists Have Been Prescribing and What the ROS1 Data Now Supports
4
Tec/Dara Offers a Path Forward in Relapsed Myeloma When CAR T Is Not an Option
5